As pharma's earnings reports rolled out for the second quarter, market watchers pointed out a big positive: Growth rates, for many companies at least, were up. Way up.
Now that the industry's top players have all rolled out their numbers, we've delved into sales figures from Big Pharma through closely watched specialty pharmas and big biotechs. And some companies truly did churn out better-than-expected growth. AstraZeneca, we're looking at you and your 18% hike, for instance.